68Ga-PSMA PET in the Renal Cell Carcinoma
Recruiting
N/A
Interventional Study
Renal Cancer
Metastases
PSMA PET
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 300 (estimated)
- Sponsor
- Xijing Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 2017 AJCC renal cell carcinoma TNM stage III, IV lesions;
* In contrast-enhanced CT staging, suspicious metastases were found;
* There were no known peripheral or central venous problems;
* 68Ga PSMA PET / CT imaging can be performed within 6 weeks after the diagnosis of renal…
Contacts
No contact information available.